+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Initial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancer



Initial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancer



Biomarkers in Medicine 13(4): 249-258



To assessed the prognostic significance of pretreatment platelet-to-lymphocyte ratio (PLR) in patients with limited-stage small cell lung cancer (LS-SCLC). We retrospectively analyzed 286 patients with LS-SCLC. Sixty received chemotherapy alone, 158 sequential chemo- and radiotherapy, 38 concurrent chemo- and radiotherapy and 30 surgery combined with therapy. The cut-off value of pretreatment PLR was 152.1. The median progression free survival (PFS) and overall survival (OS) in the low and high PLR groups were 27.4 versus 19.5 (p = 0.002) and 14.9 versus 11.4 (p = 0.003) months. Multivariate analysis confirmed that PLR was an independent prognostic factor of OS (hazard ratio = 1.326; p = 0.040) and PFS (hazard ratio = 1.306; p = 0.044), respectively. Pretreatment PLR is an independent prognostic factor of OS and PFS in patients with LS-SCLC.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066072807

Download citation: RISBibTeXText

PMID: 30624082


Related references

Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clinical Lung Cancer 20(2): 117-123, 2019

Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. Plos one 13(7): E0200341, 2018

Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non-small cell lung cancer. Oncotarget 8(42): 73198-73207, 2017

The Prognostic Factors of Lower Nadir of Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio Were Associated With Worse Treatment Outcomes in Patients With Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology*biology*physics 99(2): E501-E502, 2017

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. RadioTherapy and Oncology 126(3): 499-505, 2018

Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy. Cancer Management and Research 10: 6677-6683, 2018

Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. Journal of Thoracic Oncology 10(2): 280-285, 2015

Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer 75(2): 223-227, 2012

Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Medical Oncology 30(1): 352, 2013

Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer. Tumour Biology 37(1): 971-978, 2016

The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy. Indian Journal of Cancer 55(3): 276-281, 2018

Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study. Plos one 10(5): E0126496, 2015

Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer. Cancer Management and Research 10: 5411-5422, 2018

Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non-small-cell lung cancer. Future Oncology 13(1): 51-61, 2017

Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thoracic Cancer 6(3): 275-287, 2015